Trial Profile
Specific active immunotherapy with the vaccine NGcGM3/VSSP in patients with metastatic hormone-receptor positive and HER2 negative breast cancer
Status:
Not yet recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 16 Oct 2020
Price :
$35
*
At a glance
- Drugs N-glycolyl GM3 vaccine (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- 13 Dec 2016 New trial record